Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$2.31
+6.5%
$2.47
$1.28
$7.85
$238.46M1.31.09 million shs1.96 million shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.41
+2.6%
$3.35
$1.89
$11.64
$62.48M0.972.50 million shs644,216 shs
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
$1.62
-1.2%
$1.38
$0.61
$17.19
$262.35M2.911.13 million shs338,797 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.17
$1.78
$0.13
$3.29
$274.90M2.067.88 million shs2.86 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
+6.45%-5.33%-6.85%+9.48%-60.91%
INmune Bio, Inc. stock logo
INMB
INmune Bio
+2.55%-4.74%-15.73%-66.99%-64.82%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-1.22%-0.61%-12.43%+138.34%-86.63%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.00%+1.40%+3.83%+1,128.77%+117.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Annexon, Inc. stock logo
ANNX
Annexon
2.7324 of 5 stars
3.43.00.00.03.12.50.0
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.9926 of 5 stars
3.32.00.00.01.51.70.6
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
2.3628 of 5 stars
3.13.00.00.01.42.50.6
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
1.9451 of 5 stars
3.30.00.00.01.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
2.75
Moderate Buy$12.50441.13% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.57
Moderate Buy$18.40663.49% Upside
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
2.22
Hold$7.14340.92% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.56
Moderate Buy$6.07179.57% Upside

Current Analyst Ratings Breakdown

Latest INMB, ANNX, NMRA, and VOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Annexon, Inc. stock logo
ANNX
Annexon
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/15/2025
Annexon, Inc. stock logo
ANNX
Annexon
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
8/14/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
7/16/2025
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.00
7/2/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $8.00
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
6/30/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Outperform
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.81 per shareN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$50K1,281.40N/AN/A$1.09 per share2.21
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/A$1.13 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$243.79M-$1.57N/AN/AN/AN/A-98.95%-87.68%11/11/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$13.66N/AN/AN/AN/AN/AN/AN/A

Latest INMB, ANNX, NMRA, and VOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Annexon, Inc. stock logo
ANNX
Annexon
-$0.36-$0.34+$0.02-$0.34N/AN/A
8/7/2025Q2 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A
8/6/2025Q2 2025
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$0.38-$0.33+$0.05-$0.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.67
7.99
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
4.20
4.20
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
0.11
10.54
10.54
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
47.65%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Annexon, Inc. stock logo
ANNX
Annexon
11.87%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
26.80%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60109.89 million96.84 millionOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1026.59 million17.09 millionOptionable
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
108161.95 million118.54 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140126.68 million65.45 millionNot Optionable

Recent News About These Companies

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright
HC Wainwright Lowers Earnings Estimates for Vor Biopharma
Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright
Wedbush Comments on Vor Biopharma's Q3 Earnings (NYSE:VOR)
Vor Biopharma Announces Key Leadership Changes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Annexon stock logo

Annexon NASDAQ:ANNX

$2.31 +0.14 (+6.45%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.30 -0.01 (-0.43%)
As of 08/22/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.41 +0.06 (+2.55%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.36 -0.05 (-2.03%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Neumora Therapeutics stock logo

Neumora Therapeutics NASDAQ:NMRA

$1.62 -0.02 (-1.22%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.02 (+1.23%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.17 0.00 (0.00%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.19 +0.02 (+1.15%)
As of 08/22/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.